Chemomab Therapeutics Ltd. (NASDAQ:CMMB) Short Interest Update

Chemomab Therapeutics Ltd. (NASDAQ:CMMB) was the recipient of a significant growth in short interest in December. As of December 15th, there was short interest totalling 111,600 shares, a growth of 8.2% from the November 30th total of 103,100 shares. Approximately 0.7% of the shares of the company are short sold. Based on an average daily trading volume, of 118,500 shares, the short-interest ratio is presently 0.9 days.

Institutional Trading of Chemomab Therapeutics

An institutional investor recently bought a new position in Chemomab Therapeutics stock. Sphera Funds Management LTD. bought a new stake in Chemomab Therapeutics Ltd. (NASDAQ:CMMB) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 1,214,575 shares of the company’s stock, valued at approximately $1,907,000. Sphera Funds Management LTD. owned about 8.46% of Chemomab Therapeutics at the end of the most recent quarter. 46.05% of the stock is owned by hedge funds and other institutional investors.

Chemomab Therapeutics Trading Down 10.4 %

NASDAQ CMMB opened at $1.81 on Thursday. Chemomab Therapeutics has a 1-year low of $0.46 and a 1-year high of $2.55. The stock’s 50 day moving average is $1.65 and its two-hundred day moving average is $1.46. The company has a market capitalization of $25.99 million, a price-to-earnings ratio of -1.81 and a beta of 0.66.

Analyst Ratings Changes

Separately, Oppenheimer restated an “outperform” rating and issued a $11.00 price objective (down previously from $13.00) on shares of Chemomab Therapeutics in a research note on Friday, November 15th.

About Chemomab Therapeutics

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).